Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.

Vrabel D, Sedlarikova L, Besse L, Rihova L, Bezdekova R, Almasi M, Kubaczkova V, Brožová L, Jarkovsky J, Plonkova H, Jelinek T, Sandecka V, Stork M, Pour L, Sevcikova S, Hajek R.

Eur J Haematol. 2019 Nov 25. doi: 10.1111/ejh.13358. [Epub ahead of print]

PMID:
31763708
2.

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C; Swiss Group for Clinical Cancer Research SAKK.

Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2.

3.

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.

Cagney DN, Lamba N, Montoya S, Li P, Besse L, Martin AM, Brigell RH, Catalano PJ, Brown PD, Leone JP, Tanguturi SK, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA.

Breast Cancer Res Treat. 2019 Jul;176(1):171-179. doi: 10.1007/s10549-019-05236-6. Epub 2019 Apr 13.

PMID:
30982195
4.

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.

Besse L, Besse A, Mendez-Lopez M, Vasickova K, Sedlackova M, Vanhara P, Kraus M, Bader J, Ferreira RB, Castellano RK, Law BK, Driessen C.

Haematologica. 2019 Sep;104(9):e415-e419. doi: 10.3324/haematol.2018.207704. Epub 2019 Feb 21. No abstract available.

5.

Local control after brain-directed radiation in patients with cystic versus solid brain metastases.

Brigell RH, Cagney DN, Martin AM, Besse LA, Catalano PJ, Lee EQ, Wen PY, Brown PD, Phillips JG, Pashtan IM, Tanguturi SK, Haas-Kogan DA, Alexander BM, Aizer AA.

J Neurooncol. 2019 Apr;142(2):355-363. doi: 10.1007/s11060-019-03106-1. Epub 2019 Feb 4.

PMID:
30715665
6.

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.

Besse A, Besse L, Kraus M, Mendez-Lopez M, Bader J, Xin BT, de Bruin G, Maurits E, Overkleeft HS, Driessen C.

Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3. doi: 10.1016/j.chembiol.2018.11.007. Epub 2019 Jan 3.

PMID:
30612952
7.

Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis.

Lamba N, Cagney DN, Brigell RH, Martin AM, Besse LA, Catalano PJ, Phillips JG, Pashtan IM, Bi WL, Claus EB, Golby AJ, Dunn IF, Smith TR, Tanguturi SK, Haas-Kogan DA, Alexander BM, Aizer AA.

World Neurosurg. 2019 Feb;122:e1557-e1561. doi: 10.1016/j.wneu.2018.11.100. Epub 2018 Nov 22.

PMID:
30471438
8.

Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.

Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlíček P, Roziakova L, Penka M, Hájek R, Vasku A, Sevcikova S.

Klin Onkol. Spring 2018;31(3):213-229. doi: 10.14735/amko2018213.

PMID:
30441975
9.

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.

Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T.

Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20. No abstract available.

10.

EB1 contributes to microtubule bundling and organization, along with root growth, in Arabidopsis thaliana.

Molines AT, Marion J, Chabout S, Besse L, Dompierre JP, Mouille G, Coquelle FM.

Biol Open. 2018 Aug 2;7(8). pii: bio030510. doi: 10.1242/bio.030510.

11.

The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.

Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K.

JOR Spine. 2018 Mar 15;1(1):e1003. doi: 10.1002/jsp2.1003. eCollection 2018 Mar. Review.

12.

Multiscale and Multimodal Approaches to Study Autophagy in Model Plants.

Marion J, Le Bars R, Besse L, Batoko H, Satiat-Jeunemaitre B.

Cells. 2018 Jan 9;7(1). pii: E5. doi: 10.3390/cells7010005. Review.

13.

Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.

Abt D, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, Vodinska M, Slaby O, Schmid HP, Engeler DS, Driessen C, Besse L.

BJU Int. 2018 Apr;121(4):600-609. doi: 10.1111/bju.14083. Epub 2017 Dec 10.

14.

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.

Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C.

Blood Cancer J. 2017 Jul 28;7(7):e589. doi: 10.1038/bcj.2017.69. No abstract available.

15.

Cell-free DNA - Minimally invasive marker of hematological malignancies.

Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S.

Eur J Haematol. 2017 Oct;99(4):291-299. doi: 10.1111/ejh.12925. Epub 2017 Aug 3. Review.

PMID:
28692178
16.

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.

Besse A, Stolze SC, Rasche L, Weinhold N, Morgan GJ, Kraus M, Bader J, Overkleeft HS, Besse L, Driessen C.

Leukemia. 2018 Feb;32(2):391-401. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5.

17.

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.

Soriano GP, Besse L, Li N, Kraus M, Besse A, Meeuwenoord N, Bader J, Everts B, den Dulk H, Overkleeft HS, Florea BI, Driessen C.

Leukemia. 2016 Nov;30(11):2198-2207. doi: 10.1038/leu.2016.102. Epub 2016 Apr 27.

18.

Cytogenetics in multiple myeloma patients progressing into extramedullary disease.

Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S.

Eur J Haematol. 2016 Jul;97(1):93-100. doi: 10.1111/ejh.12688. Epub 2015 Oct 19.

PMID:
26432667
19.

MicroRNAs in urine are not biomarkers of multiple myeloma.

Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S.

J Negat Results Biomed. 2015 Sep 23;14:16. doi: 10.1186/s12952-015-0035-7.

20.

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R.

PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. eCollection 2015.

21.

[Potential of Cell-free Circulating DNA in Diagnosis of Cancer].

Kubaczková V, Sedlaříková L, Bešše L, Almaši M, Hájek R, Ševčíková S.

Klin Onkol. 2015;28(4):251-9. Review. Czech.

PMID:
26299738
22.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C.

Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23.

23.

The role of primary cilia in corpus callosum formation is mediated by production of the Gli3 repressor.

Laclef C, Anselme I, Besse L, Catala M, Palmyre A, Baas D, Paschaki M, Pedraza M, Métin C, Durand B, Schneider-Maunoury S.

Hum Mol Genet. 2015 Sep 1;24(17):4997-5014. doi: 10.1093/hmg/ddv221. Epub 2015 Jun 12.

PMID:
26071364
24.

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data.

Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M, Pour L, Hajek R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):288-93. doi: 10.5507/bp.2015.014. Epub 2015 Apr 16.

25.

[Cereblon -  a new target of therapy in the treatment of multiple myeloma].

Staňková M, Bešše L, Sedlaříková L, Vrábel D, Hájek R, Sevčíková S.

Klin Onkol. 2014;27(5):326-30. Review. Czech.

PMID:
25312709
26.

[New forms of health care coordination in geriatrics].

Tudrej BV, Hervé C, Pradere C, Besse L, Alonso L, Quoirin E, Lardeur JY, Paccalin M.

Soins Gerontol. 2014 May-Jun;(107):20-4. French.

PMID:
24908843
27.

Primary cilia control telencephalic patterning and morphogenesis via Gli3 proteolytic processing.

Besse L, Neti M, Anselme I, Gerhardt C, Rüther U, Laclef C, Schneider-Maunoury S.

Development. 2011 May;138(10):2079-88. doi: 10.1242/dev.059808. Epub 2011 Apr 13.

28.

Primary cilia are required for cerebellar development and Shh-dependent expansion of progenitor pool.

Spassky N, Han YG, Aguilar A, Strehl L, Besse L, Laclef C, Ros MR, Garcia-Verdugo JM, Alvarez-Buylla A.

Dev Biol. 2008 May 1;317(1):246-59. doi: 10.1016/j.ydbio.2008.02.026. Epub 2008 Mar 4.

29.

[Stem cell biology and therapeutic hopes: forbidden game?].

Carron C, Besse L, Besse A, Durand C.

Morphologie. 2007 Mar;91(292):14-23. Review. French.

PMID:
17631406
30.

The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome.

Delous M, Baala L, Salomon R, Laclef C, Vierkotten J, Tory K, Golzio C, Lacoste T, Besse L, Ozilou C, Moutkine I, Hellman NE, Anselme I, Silbermann F, Vesque C, Gerhardt C, Rattenberry E, Wolf MT, Gubler MC, Martinovic J, Encha-Razavi F, Boddaert N, Gonzales M, Macher MA, Nivet H, Champion G, Berthélémé JP, Niaudet P, McDonald F, Hildebrandt F, Johnson CA, Vekemans M, Antignac C, Rüther U, Schneider-Maunoury S, Attié-Bitach T, Saunier S.

Nat Genet. 2007 Jul;39(7):875-81. Epub 2007 Jun 10.

PMID:
17558409
31.

Evaluation of a new integrated discharge prescription form.

Paquette-Lamontagne N, McLean WM, Besse L, Cusson J.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):953-8.

PMID:
11485150
32.

Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives.

Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M, Evrard P.

J Pharmacol Exp Ther. 1999 Mar;288(3):1207-13.

PMID:
10027860
33.

Maternal protein restriction early in rat pregnancy alters brain development in the progeny.

Gressens P, Muaku SM, Besse L, Nsegbe E, Gallego J, Delpech B, Gaultier C, Evrard P, Ketelslegers JM, Maiter D.

Brain Res Dev Brain Res. 1997 Oct 20;103(1):21-35.

PMID:
9370057

Supplemental Content

Support Center